Skip to main content
Public Health

PERCH - PartnERship to Contrast HPV

HPV can cause cervical cancer in women and anogenital and head and neck cancers in both sexes. HPV 16 and HPV 18 genotypes cause around 70% of cases of cervical cancer, which kills around 26 000 women a year in Europe.

Cervical cancer is highly preventable through HPV vaccination and screening. However, in 2020 vaccination programme coverage in the WHO European region was only 31%.

PERCH supports national HPV vaccination efforts by improving:

  • EU Member State capacities to plan and implement vaccination campaigns;
  • HPV vaccination and cervical cancer screening data and monitoring systems;
  • awareness of HPV-related disease and its prevention among adolescents;
  • healthcare professionals’ abilities to communicate the need for vaccination.
EU4health - Projects
  • Prevention
8 AUGUST 2023
4 JUNE 2024
EU Funding & Tenders Portal - PERCH


Short-term outcomes

  • Increased awareness of how HPV vaccination and cervical cancer screening are implemented and monitored in Member States.
  • Increased awareness of the benefits of HPV vaccination among target groups.
  • Stronger national and international stakeholder networks.
  • Empowerment of countries to obtain HPV vaccines at the lowest possible price.

Medium/long-term outcomes

  • Increased HPV vaccine coverage in all or most European countries.
  • European cervical cancer incidence of less than four per 100 000 per year.
  • Reduced incidence of all HPV-related cancers and associated mortality in Europe.





Raffaella Bucciardini

Raffaella Bucciardini
Istituto Superiore di Sanità
raffaella [dot] bucciardiniatiss [dot] it